Blog Posts

Flavio G Rocha: Dose density in neoadjuvant treatment for PDAC

Flavio Rocha/X

Feb 12, 2025, 17:33

Flavio G Rocha: Dose density in neoadjuvant treatment for PDAC

Flavio G Rocha, Hedinger Chair of Surgical Oncology and Physician-in-Chief OHSU Knight Cancer Institute, shared on X about recent paper by Sameer Patel et al., titled “Chemotherapy dose density is prognostic for overall survival in patients with resectable pancreas cancer: A landmark analysis of SWOG 1505” published on ACS Journals.

Authors: Sameer H. Patel, Sarah Colby, Davendra Sohal, Katherine A. Guthrie, Lisa A. Kachnic, E. Gabriela Chiorean, Andrew M. Lowy, Flavio G. Rocha, Howard S. Hochster, Philip A. Philip, Syed A. Ahmad

“Dose density in neoadjuvant treatment for PDAC

A landmark analysis of SWOG S1505
DD >85% pre or DD >70% periop lead to OS benefit

Kudos to investigators and lead author Dr. Sameer Patel.“

Andrew M. Lowy cancer Davendra Sohal E. Gabriela Chiorean Flavio G. Rocha Howard S Hochster Katherine A. Guthrie Lisa A. Kachnic OncoDaily Oncology Philip A. Philip Sameer H. Patel Sarah Colby Syed A. Ahmad

Aparna Parikh Has Been Named Program Director for the GI Medical Oncology Program at Mass General Brigham

Herbert Loong: Grateful for the Journey with ASCO International Affairs Committee

Unreleased Decision Letters From 2024–2025 Now Available - FDA

Servier and IDEAYA Biosciences Partner to Advance Darovasertib for Uveal Melanoma

FDA Grants Breakthrough Therapy Designation to Zongertinib (HERNEXEOS) for First-Line Treatment of HER2-Mutant Advanced NSCLC